Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
mutations	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
YanXing	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
YanXing	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
mutations	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
YanXing	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O
YanXing	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
mutations	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
mutations	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
YanXing	O
Investigational	O
Cancer	O
Therapeutics	O

Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O
YanXing	O
Investigational	O
Cancer	O
Therapeutics	O

USA	O
08540	O
Princeton	O
NJ	O
USA	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
mutations	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
10.1186	O
/	O
s13058	O
-	O
019	O
-	O
1154	O
-	O
8	O
Received	O
:	O

USA	O
08540	O
Princeton	O
NJ	O
USA	O
Phase	O
II	O
trial	O
of	O
AKT	O
inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
PIK3CA	O
or	O
AKT	O
mutations	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O
10.1186	O
/	O
s13058	O
-	O
019	O
-	O
1154	O
-	O
8	O
Received	O
:	O

"	O
Phase	O
II	O
Trial	O
of	O
AKT	O
Inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
a	O
[P1]	O
PIK3CA	O
mutation	O
,	O
or	O
an	O
AKT	O
mutation	O
[P2]	O
,	O
and/or	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
"	O
(	O
NCT01277757	O
)	O
was	O
a	O
phase	O
II	O
trial	O
sponsored	O
by	O
The	O
Cancer	O
Therapy	O
Evaluation	O
Program	O
and	O
conducted	O
by	O
the	O
American	O
Academy	O
of	O
Cancer	O
Research	O
Stand	O
Up	O
to	O
Cancer	O
PI3	O
K	O
Dream	O
Team	O
.	O

"	O
Phase	O
II	O
Trial	O
of	O
AKT	O
Inhibitor	O
MK-2206	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
have	O
tumors	O
with	O
a	O
PIK3CA	O
mutation	O
,	O
or	O
an	O
AKT	O
mutation	O
,	O
and/or	O
[P1]	O
PTEN	O
loss	O
/	O
PTEN	O
mutation	O
[P2]	O
"	O
(	O
NCT01277757	O
)	O
was	O
a	O
phase	O
II	O
trial	O
sponsored	O
by	O
The	O
Cancer	O
Therapy	O
Evaluation	O
Program	O
and	O
conducted	O
by	O
the	O
American	O
Academy	O
of	O
Cancer	O
Research	O
Stand	O
Up	O
to	O
Cancer	O
PI3	O
K	O
Dream	O
Team	O
.	O

Patients	O
with	O
histologically	O
or	O
cytologically	O
confirmed	O
breast	O
cancer	O
and	O
with	O
metastatic	O
/	O
advanced	O
disease	O
were	O
eligible	O
for	O
enrollment	O
for	O
screening	O
for	O
[P1]	O
PIK3CA	O
,	O
AKT	O
[P2]	O
,	O
and	O
PTEN	O
status	O
after	O
informed	O
consent	O
.	O

Patients	O
with	O
histologically	O
or	O
cytologically	O
confirmed	O
breast	O
cancer	O
and	O
with	O
metastatic	O
/	O
advanced	O
disease	O
were	O
eligible	O
for	O
enrollment	O
for	O
screening	O
for	O
PIK3CA	O
,	O
AKT	O
,	O
and	O
[P1]	O
PTEN	O
[P2]	O
status	O
after	O
informed	O
consent	O
.	O

Patients	O
with	O
[P1]	O
PIK3CA	O
/	O
AKT	O
[P2]	O
/	O
PTEN	O
alterations	O
were	O
eligible	O
to	O
consent	O
on	O
the	O
treatment	O
protocol	O
on	O
one	O
of	O
two	O
cohorts	O
:	O
(	O

1	O
)	O
activating	O
PIK3CA	O
or	O
AKT1	O
mutations	O
or	O
(	O
2	O
)	O
[P1]	O
PTEN	O
mutation	O
or	O
PTEN	O
loss	O
[P2]	O
(	O
by	O
IHC	O
)	O
.	O

Although	O
central	O
testing	O
was	O
offered	O
,	O
patients	O
whose	O
tumors	O
have	O
already	O
been	O
tested	O
in	O
a	O
CLIA	O
laboratory	O
environment	O
and	O
found	O
to	O
have	O
a	O
[P1]	O
PIK3CA	O
or	O
AKT	O
[P2]	O
mutation	O
or	O
PTEN	O
loss	O
or	O
mutation	O
were	O
also	O
eligible	O
.	O

Although	O
central	O
testing	O
was	O
offered	O
,	O
patients	O
whose	O
tumors	O
have	O
already	O
been	O
tested	O
in	O
a	O
CLIA	O
laboratory	O
environment	O
and	O
found	O
to	O
have	O
a	O
PIK3CA	O
or	O
AKT	O
mutation	O
or	O
[P1]	O
PTEN	O
loss	O
or	O
mutation	O
[P2]	O
were	O
also	O
eligible	O
.	O

The	O
primary	O
objective	O
was	O
to	O
determine	O
whether	O
MK-2206	O
was	O
associated	O
with	O
objective	O
tumor	O
responses	O
(	O
complete	O
response	O
[	O
CR	O
]	O
,	O
partial	O
response	O
[	O
PR	O
]	O
)	O
in	O
advanced	O
breast	O
cancer	O
patients	O
with	O
[P1]	O
PIK3CA	O
or	O
AKT	O
[P2]	O
mutation	O
and/or	O
PTEN	O
loss	O
or	O
mutation	O
.	O

The	O
primary	O
objective	O
was	O
to	O
determine	O
whether	O
MK-2206	O
was	O
associated	O
with	O
objective	O
tumor	O
responses	O
(	O
complete	O
response	O
[	O
CR	O
]	O
,	O
partial	O
response	O
[	O
PR	O
]	O
)	O
in	O
advanced	O
breast	O
cancer	O
patients	O
with	O
PIK3CA	O
or	O
AKT	O
mutation	O
and/or	O
[P1]	O
PTEN	O
loss	O
or	O
mutation	O
[P2]	O
.	O

Patients	O
received	O
[P1]	O
MK-2206	O
[P2]	O
200	B-arm_dosage
mg	I-arm_dosage
orally	I-arm_dosage
once	I-arm_dosage
a	I-arm_dosage
week	I-arm_dosage
,	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O

[P1]	O
PTEN	O
[P2]	O
IHC	O
was	O
performed	O
in	O
the	O
MD	O
Anderson	O
CLIA	O
clinical	O
laboratory	O
.	O

[P1]	O
PTEN	O
[P2]	O
IHC	O
was	O
performed	O
using	O
monoclonal	O
mouse	O
anti	O
-	O
Human	O
PTEN	O
antibody	O
Clone	O
6H2.1	O
from	O
Dako	O
at	O
1:100	O
dilution	O
.	O

PTEN	O
IHC	O
was	O
performed	O
using	O
monoclonal	O
mouse	O
anti	O
-	O
Human	O
[P1]	O
PTEN	O
[P2]	O
antibody	O
Clone	O
6H2.1	O
from	O
Dako	O
at	O
1:100	O
dilution	O
.	O

In	O
previous	O
studies	O
,	O
we	O
had	O
already	O
demonstrated	O
that	O
[P1]	O
PTEN	O
loss	O
[P2]	O
by	O
IHC	O
is	O
associated	O
with	O
PI3	O
K	O
pathway	O
activation	O
[	O
7	O
]	O
.	O

[P1]	O
PTEN	O
[P2]	O
staining	O
was	O
evaluated	O
by	O
assessing	O
both	O
intensity	O
and	O
percent	O
positivity	O
of	O
staining	O
.	O

Any	O
tumor	O
nuclear	O
or	O
cytoplasmic	O
staining	O
showing	O
similar	O
intensity	O
with	O
internal	O
control	O
cells	O
was	O
considered	O
positive	O
staining	O
(	O
no	O
[P1]	O
PTEN	O
loss	O
[P2]	O
)	O
.	O

Complete	O
lack	O
of	O
staining	O
or	O
faint	O
staining	O
(	O
cytoplasmic	O
or	O
nuclear	O
)	O
in	O
up	O
to	O
50	O
%	O
of	O
tumor	O
cells	O
was	O
considered	O
as	O
[P1]	O
PTEN	O
loss	O
[P2]	O
.	O

CLIA	O
DNA	O
analysis	O
was	O
performed	O
initially	O
using	O
the	O
Sanger	O
sequencing	O
,	O
and	O
then	O
transitioned	O
to	O
mass	O
spectroscopy	O
-	O
based	O
multiplex	O
assay	O
to	O
assess	O
the	O
mutational	O
status	O
of	O
hotspot	O
regions	O
in	O
11	O
genes	O
(	O
Sequenom	O
)	O
or	O
with	O
next	O
-	O
generation	O
sequencing	O
using	O
the	O
Ion	O
Ampliseq	O
46	O
Gene	O
Cancer	O
Panel	O
(	O
Life	O
Technologies	O
)	O
to	O
assess	O
hotspot	O
mutations	O
in	O
[P1]	O
PIK3CA	O
and	O
AKT1	O
[P2]	O
genes	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

We	O
used	O
a	O
Bayesian	O
adaptive	O
phase	O
II	O
design	O
for	O
singleagent	O
[P1]	O
MK-2206	O
[P2]	O
in	O
advanced	O
breast	O
cancer	O
.	O

There	O
were	O
two	O
cohorts	O
of	O
patients	O
,	O
[P1]	O
PIK3CA/	O
AKT1	O
[P2]	O
mutant	O
vs.	O
PTEN	O
loss	O
;	O

There	O
were	O
two	O
cohorts	O
of	O
patients	O
,	O
PIK3CA/	O
AKT1	O
mutant	O
vs.	O
[P1]	O
PTEN	O
loss	O
[P2]	O
;	O

Twenty	O
-	O
seven	O
patients	O
received	O
[P1]	O
MK-2206	O
[P2]	O
treatment	O
:	O

18	O
patients	O
were	O
treated	O
on	O
the	O
[P1]	O
PIK3CA	O
/	O
AKT1	O
mutation	O
arm	O
[P2]	O
(	O
cohort	O
A)-13	O
had	O
PIK3CA	O
mutations	O
,	O
4	O
had	O
AKT1	O
mutations	O
,	O
and	O
one	O
had	O
a	O
PIK3CA	O
mutation	O
as	O
well	O
as	O
PTEN	O
loss	O
.	O

18	O
patients	O
were	O
treated	O
on	O
the	O
PIK3CA	O
/	O
AKT1	O
mutation	O
arm	O
(	O
cohort	O
A)-13	O
had	O
[P1]	O
PIK3CA	O
[P2]	O
mutations	O
,	O
4	O
had	O
AKT1	O
mutations	O
,	O
and	O
one	O
had	O
a	O
PIK3CA	O
mutation	O
as	O
well	O
as	O
PTEN	O
loss	O
.	O

18	O
patients	O
were	O
treated	O
on	O
the	O
PIK3CA	O
/	O
AKT1	O
mutation	O
arm	O
(	O
cohort	O
A)-13	O
had	O
PIK3CA	O
mutations	O
,	O
4	O
had	O
[P1]	O
AKT1	O
[P2]	O
mutations	O
,	O
and	O
one	O
had	O
a	O
PIK3CA	O
mutation	O
as	O
well	O
as	O
PTEN	O
loss	O
.	O

18	O
patients	O
were	O
treated	O
on	O
the	O
PIK3CA	O
/	O
AKT1	O
mutation	O
arm	O
(	O
cohort	O
A)-13	O
had	O
PIK3CA	O
mutations	O
,	O
4	O
had	O
AKT1	O
mutations	O
,	O
and	O
one	O
had	O
a	O
[P1]	O
PIK3CA	O
[P2]	O
mutation	O
as	O
well	O
as	O
PTEN	O
loss	O
.	O

Nine	O
patients	O
were	O
enrolled	O
on	O
the	O
[P1]	O
PTEN	O
mutation	O
/	O
loss	O
arm	O
[P2]	O
(	O
cohort	O
B	O
)	O
:	O

4	O
with	O
[P1]	O
PTEN	O
mutations	O
[P2]	O
and	O
5	O
with	O
PTEN	O
loss	O
by	O
IHC	O
.	O

4	O
with	O
PTEN	O
mutations	O
and	O
5	O
with	O
[P1]	O
PTEN	O
loss	O
[P2]	O
by	O
IHC	O
.	O

In	O
stage	O
I	O
of	O
the	O
study	O
,	O
we	O
observed	O
a	O
confirmed	O
partial	O
response	O
in	O
a	O
patient	O
with	O
a	O
breast	O
cancer	O
bearing	O
a	O
[P1]	O
PIK3CA	O
[P2]	O
mutation	O
.	O

By	O
our	O
adaptive	O
design	O
,	O
one	O
objective	O
response	O
fulfilled	O
stage	O
I	O
criteria	O
for	O
response	O
,	O
thus	O
both	O
[P1]	O
PIK3CA	O
/	O
AKT	O
[P2]	O
and	O
PTEN	O
loss	O
/	O
mutation	O
cohorts	O
proceeded	O
to	O
accrue	O
.	O

By	O
our	O
adaptive	O
design	O
,	O
one	O
objective	O
response	O
fulfilled	O
stage	O
I	O
criteria	O
for	O
response	O
,	O
thus	O
both	O
PIK3CA	O
/	O
AKT	O
and	O
[P1]	O
PTEN	O
loss	O
/	O
mutation	O
cohorts	O
[P2]	O
proceeded	O
to	O
accrue	O
.	O

If	O
there	O
were	O
no	O
further	O
responses	O
seen	O
,	O
based	O
on	O
the	O
initial	O
statistical	O
plan	O
,	O
we	O
would	O
be	O
expected	O
to	O
treat	O
20	O
evaluable	O
patients	O
on	O
the	O
[P1]	O
PIK3CA/	O
AKT	O
arm	O
[P2]	O
and	O
12	O
patients	O
on	O
the	O
PTEN	O
loss	O
arm	O
before	O
clinical	O
futility	O
would	O
be	O
declared	O
and	O
trial	O
terminated	O
.	O

If	O
there	O
were	O
no	O
further	O
responses	O
seen	O
,	O
based	O
on	O
the	O
initial	O
statistical	O
plan	O
,	O
we	O
would	O
be	O
expected	O
to	O
treat	O
20	O
evaluable	O
patients	O
on	O
the	O
PIK3CA/	O
AKT	O
arm	O
and	O
12	O
patients	O
on	O
the	O
[P1]	O
PTEN	O
loss	O
arm	O
[P2]	O
before	O
clinical	O
futility	O
would	O
be	O
declared	O
and	O
trial	O
terminated	O
.	O

Eighteen	O
patients	O
were	O
enrolled	O
in	O
the	O
[P1]	O
PIK3CA	O
/	O
AKT	O
cohort	O
[P2]	O
.	O

Of	O
14	O
patients	O
with	O
[P1]	O
PIK3CA	O
[P2]	O
mutations	O
,	O
one	O
patient	O
had	O
a	O
partial	O
response	O
(	O
described	O
below	O
)	O
.	O

One	O
patient	O
with	O
both	O
a	O
[P1]	O
PIK3CA	O
[P2]	O
mutation	O
and	O
PTEN	O
loss	O
was	O
assigned	O
to	O
the	O
PIK3CA	O
/	O
AKT	O
arm	O
and	O
did	O
not	O
respond	O
to	O
treatment	O
.	O

One	O
patient	O
with	O
both	O
a	O
PIK3CA	O
mutation	O
and	O
PTEN	O
loss	O
was	O
assigned	O
to	O
the	O
[P1]	O
PIK3CA	O
/	O
AKT	O
[P2]	O
arm	O
and	O
did	O
not	O
respond	O
to	O
treatment	O
.	O

Four	O
patients	O
with	O
[P1]	O
AKT	O
[P2]	O
E17	O
K	O
mutations	O
were	O
also	O
enrolled	O
with	O
no	O
objective	O
responses	O
.	O

The	O
patient	O
who	O
had	O
a	O
confirmed	O
partial	O
response	O
in	O
the	O
[P1]	O
PIK3CA	O
/	O
AKT	O
cohort	O
[P2]	O
had	O
metastatic	O
ER+	O
,	O
PR-	O
,	O
and	O
HER2-breast	O
cancer	O
with	O
a	O
PIK3CA	O
E542	O
K	O
mutation	O
.	O

The	O
patient	O
who	O
had	O
a	O
confirmed	O
partial	O
response	O
in	O
the	O
PIK3CA	O
/	O
AKT	O
cohort	O
had	O
metastatic	O
ER+	O
,	O
PR-	O
,	O
and	O
HER2-breast	O
cancer	O
with	O
a	O
[P1]	O
PIK3CA	O
[P2]	O
E542	O
K	O
mutation	O
.	O

Nine	O
patients	O
were	O
enrolled	O
in	O
the	O
[P1]	O
PTEN	O
loss	O
/	O
mutation	O
cohort	O
[P2]	O
:	O

Patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
[P1]	O
MK-2206	O
[P2]	O
were	O
considered	O
eligible	O
for	O
toxicity	O
assessment	O
.	O

Depicting	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
for	O
[P1]	O
PTEN	O
cohort	O
[P2]	O
(	O
blue	O
)	O
,	O
and	O
PFS	B-arm_efficacy_metric
for	O
PIK3CA	O
/	O
AKT	O
cohort	O
(	O
red	O
)	O
.	O

Depicting	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
for	O
PTEN	O
cohort	O
(	O
blue	O
)	O
,	O
and	O
PFS	O
for	O
[P1]	O
PIK3CA	O
/	O
AKT	O
[P2]	O
cohort	O
(	O
red	O
)	O
.	O

Patients	O
who	O
discontinued	O
[P1]	O
MK-2206	O
[P2]	O
due	O
to	O
toxicity	O
are	O
depicted	O
with	O
a	O
(	O
#	O
)	O
,	O
while	O
patients	O
who	O
discontinued	O
MK-2206	O
due	O
to	O
patient	O
choice	O
are	O
depicted	O
with	O
a	O
(	O
*	O
)	O
.	O

Patients	O
who	O
discontinued	O
MK-2206	O
due	O
to	O
toxicity	O
are	O
depicted	O
with	O
a	O
(	O
#	O
)	O
,	O
while	O
patients	O
who	O
discontinued	O
[P1]	O
MK-2206	O
[P2]	O
due	O
to	O
patient	O
choice	O
are	O
depicted	O
with	O
a	O
(	O
*	O
)	O
.	O

Two	O
patients	O
who	O
were	O
enrolled	O
on	O
the	O
[P1]	O
PTEN	O
loss	O
cohort	O
[P2]	O
had	O
PTEN	O
expressions	O
on	O
the	O
pre	O
-	O
treatment	O
biopsy	O
sample	O
are	O
depicted	O
with	O
a	O
(	O
&	O
)	O
.	O

Two	O
patients	O
who	O
were	O
enrolled	O
on	O
the	O
PTEN	O
loss	O
cohort	O
had	O
[P1]	O
PTEN	O
[P2]	O
expressions	O
on	O
the	O
pre	O
-	O
treatment	O
biopsy	O
sample	O
are	O
depicted	O
with	O
a	O
(	O
&	O
)	O
.	O

A	O
patient	O
who	O
had	O
both	O
[P1]	O
PTEN	O
loss	O
[P2]	O
and	O
PIK3CA	O
mutation	O
is	O
depicted	O
with	O
a	O
(	O
^	O
)	O
.	O

A	O
patient	O
who	O
had	O
both	O
PTEN	O
loss	O
and	O
[P1]	O
PIK3CA	O
[P2]	O
mutation	O
is	O
depicted	O
with	O
a	O
(	O
^	O
)	O
.	O

A	O
diagnosis	O
of	O
cancer	O
-	O
associated	O
MAHA	O
was	O
made	O
,	O
and	O
the	O
event	O
was	O
deemed	O
probably	O
attributable	O
to	O
disease	O
progression	O
and	O
possibly	O
related	O
to	O
treatment	O
with	O
[P1]	O
MK-2206	O
[P2]	O
.	O

In	O
conclusion	O
,	O
[P1]	O
MK-2206	O
[P2]	O
monotherapy	O
had	O
limited	O
clinical	O
activity	O
in	O
advanced	O
breast	O
cancer	O
patients	O
selected	O
for	O
PIK3CA	O
/	O
AKT1	O
or	O
PTEN	O
mutations	O
or	O
PTEN	O
loss	O
.	O

In	O
conclusion	O
,	O
MK-2206	O
monotherapy	O
had	O
limited	O
clinical	O
activity	O
in	O
advanced	O
breast	O
cancer	O
patients	O
selected	O
for	O
[P1]	O
PIK3CA	O
/	O
AKT1	O
[P2]	O
or	O
PTEN	O
mutations	O
or	O
PTEN	O
loss	O
.	O

In	O
conclusion	O
,	O
MK-2206	O
monotherapy	O
had	O
limited	O
clinical	O
activity	O
in	O
advanced	O
breast	O
cancer	O
patients	O
selected	O
for	O
PIK3CA	O
/	O
AKT1	O
or	O
[P1]	O
PTEN	O
mutations	O
or	O
PTEN	O
loss	O
[P2]	O
.	O

This	O
may	O
,	O
in	O
part	O
,	O
be	O
due	O
to	O
inadequate	O
target	O
inhibition	O
at	O
tolerable	O
doses	O
in	O
heavily	O
pre	O
-	O
treated	O
patients	O
with	O
pathway	O
activation	O
,	O
as	O
well	O
as	O
tumor	O
heterogeneity	O
and	O
evolution	O
in	O
markers	O
such	O
as	O
[P1]	O
PTEN	O
[P2]	O
conferring	O
challenges	O
in	O
patient	O
selection	O
.	O

The	O
fact	O
that	O
one	O
of	O
the	O
patients	O
with	O
a	O
PR	O
had	O
an	O
activating	O
KRAS	O
mutation	O
,	O
also	O
confirmed	O
on	O
pre	O
-	O
treatment	O
biopsy	O
,	O
is	O
unexpected	O
,	O
and	O
suggests	O
that	O
the	O
simplistic	O
view	O
that	O
MAPK	O
co	O
-	O
mutations	O
would	O
confer	O
resistance	O
to	O
[P1]	O
AKT	O
[P2]	O
inhibitors	O
may	O
not	O
be	O
sufficient	O
for	O
precision	O
oncology	O
,	O
and	O
better	O
modeling	O
of	O
driver	O
mutations	O
,	O
pathway	O
activation	O
,	O
and	O
adaptive	O
responses	O
is	O
needed	O
.	O